Shaanxi Kanghui Pharm Co Ltd (603139) - Net Assets
Based on the latest financial reports, Shaanxi Kanghui Pharm Co Ltd (603139) has net assets worth CN¥581.05 Million CNY (≈ $85.03 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.71 Billion ≈ $249.51 Million USD) and total liabilities (CN¥1.12 Billion ≈ $164.48 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 603139 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥581.05 Million |
| % of Total Assets | 34.08% |
| Annual Growth Rate | 7.95% |
| 5-Year Change | -48.97% |
| 10-Year Change | 8.83% |
| Growth Volatility | 27.45 |
Shaanxi Kanghui Pharm Co Ltd - Net Assets Trend (2012–2025)
This chart illustrates how Shaanxi Kanghui Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Shaanxi Kanghui Pharm Co Ltd market cap and net worth.
Annual Net Assets for Shaanxi Kanghui Pharm Co Ltd (2012–2025)
The table below shows the annual net assets of Shaanxi Kanghui Pharm Co Ltd from 2012 to 2025. Also explore Shaanxi Kanghui Pharm Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥568.98 Million ≈ $83.26 Million |
-37.26% |
| 2024-12-31 | CN¥906.90 Million ≈ $132.71 Million |
-11.08% |
| 2023-12-31 | CN¥1.02 Billion ≈ $149.25 Million |
-0.59% |
| 2022-12-31 | CN¥1.03 Billion ≈ $150.13 Million |
-7.99% |
| 2021-12-31 | CN¥1.12 Billion ≈ $163.16 Million |
+3.92% |
| 2020-12-31 | CN¥1.07 Billion ≈ $157.00 Million |
+5.52% |
| 2019-12-31 | CN¥1.02 Billion ≈ $148.79 Million |
+3.83% |
| 2018-12-31 | CN¥979.31 Million ≈ $143.30 Million |
+7.37% |
| 2017-12-31 | CN¥912.11 Million ≈ $133.47 Million |
+74.46% |
| 2016-12-31 | CN¥522.81 Million ≈ $76.50 Million |
+14.26% |
| 2015-12-31 | CN¥457.58 Million ≈ $66.96 Million |
+15.73% |
| 2014-12-31 | CN¥395.37 Million ≈ $57.86 Million |
+18.86% |
| 2013-12-31 | CN¥332.63 Million ≈ $48.67 Million |
+58.07% |
| 2012-12-31 | CN¥210.43 Million ≈ $30.79 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shaanxi Kanghui Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 168.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥580.62 Million | 110.61% |
| Total Equity | CN¥524.92 Million | 100.00% |
Shaanxi Kanghui Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of Shaanxi Kanghui Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Australian Agricultural Company Ltd
AU:AAC
|
$554.44 Million |
|
Nuveen Dynamic Municipal Opportunities Fund
NYSE:NDMO
|
$554.64 Million |
|
Consultatio SA
BA:CTIO
|
$554.66 Million |
|
Bohai Ferry Co Ltd
SHG:603167
|
$554.70 Million |
|
Universal Cables Limited
NSE:UNIVCABLES
|
$554.20 Million |
|
Saimo Electric Co Ltd
SHE:300466
|
$554.04 Million |
|
WIA Gold Ltd
AU:WIA
|
$553.98 Million |
|
Suzhou Alton Electrical & Mechanical Industry Co. Ltd.
SHE:301187
|
$553.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shaanxi Kanghui Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 857,322,192 to 524,920,847, a change of -332,401,345 (-38.8%).
- Net loss of 333,452,128 reduced equity.
- Dividend payments of 27,855,541 reduced retained earnings.
- Other comprehensive income decreased equity by 69,210,835.
- Other factors increased equity by 98,117,159.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-333.45 Million | -63.52% |
| Dividends Paid | CN¥27.86 Million | -5.31% |
| Other Comprehensive Income | CN¥-69.21 Million | -13.19% |
| Other Changes | CN¥98.12 Million | +18.69% |
| Total Change | CN¥- | -38.77% |
Book Value vs Market Value Analysis
This analysis compares Shaanxi Kanghui Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.22x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 11.94x to 7.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥3.18 | CN¥37.93 | x |
| 2013-12-31 | CN¥4.59 | CN¥37.93 | x |
| 2014-12-31 | CN¥5.29 | CN¥37.93 | x |
| 2015-12-31 | CN¥6.11 | CN¥37.93 | x |
| 2016-12-31 | CN¥6.97 | CN¥37.93 | x |
| 2017-12-31 | CN¥9.97 | CN¥37.93 | x |
| 2018-12-31 | CN¥9.53 | CN¥37.93 | x |
| 2019-12-31 | CN¥9.84 | CN¥37.93 | x |
| 2020-12-31 | CN¥10.04 | CN¥37.93 | x |
| 2021-12-31 | CN¥10.62 | CN¥37.93 | x |
| 2022-12-31 | CN¥9.73 | CN¥37.93 | x |
| 2023-12-31 | CN¥9.43 | CN¥37.93 | x |
| 2024-12-31 | CN¥8.61 | CN¥37.93 | x |
| 2025-12-31 | CN¥5.26 | CN¥37.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shaanxi Kanghui Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -63.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -70.75%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 3.46x
- Recent ROE (-63.52%) is below the historical average (1.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 19.20% | 14.59% | 0.88x | 1.50x | CN¥19.36 Million |
| 2013 | 16.78% | 17.02% | 0.73x | 1.35x | CN¥22.56 Million |
| 2014 | 15.87% | 16.70% | 0.74x | 1.28x | CN¥23.20 Million |
| 2015 | 13.59% | 16.38% | 0.66x | 1.26x | CN¥16.45 Million |
| 2016 | 12.48% | 17.08% | 0.58x | 1.25x | CN¥12.95 Million |
| 2017 | 6.92% | 17.17% | 0.36x | 1.13x | CN¥-28.06 Million |
| 2018 | 5.88% | 14.81% | 0.34x | 1.17x | CN¥-39.02 Million |
| 2019 | 4.37% | 9.91% | 0.38x | 1.16x | CN¥-55.06 Million |
| 2020 | 3.39% | 8.24% | 0.32x | 1.30x | CN¥-66.66 Million |
| 2021 | 3.49% | 8.24% | 0.24x | 1.78x | CN¥-68.19 Million |
| 2022 | -6.48% | -12.83% | 0.27x | 1.87x | CN¥-160.43 Million |
| 2023 | -2.76% | -3.89% | 0.33x | 2.16x | CN¥-121.08 Million |
| 2024 | -10.45% | -15.96% | 0.30x | 2.20x | CN¥-175.36 Million |
| 2025 | -63.52% | -70.75% | 0.26x | 3.46x | CN¥-385.94 Million |
Industry Comparison
This section compares Shaanxi Kanghui Pharm Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,755,273,774
- Average return on equity (ROE) among peers: -4.78%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shaanxi Kanghui Pharm Co Ltd (603139) | CN¥581.05 Million | 19.20% | 1.93x | $554.37 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $805.26 Million | -92.13% | 3.95x | $585.22 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $591.07 Million | 1.62% | 0.52x | $407.31 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.12 Billion | 13.25% | 0.26x | $4.27 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.17 Billion | 7.85% | 0.81x | $2.26 Billion |
| Wedge Industrial Co Ltd (000534) | $0.00 | 0.00% | 0.00x | $1.78 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $210.25 Million | 11.37% | 0.23x | $13.33 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $875.19 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $268.78 Million | 10.37% | 0.50x | $311.17 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.74 Billion | -22.62% | 2.37x | $973.03 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $6.56 Billion | 20.83% | 0.09x | $3.07 Billion |
About Shaanxi Kanghui Pharm Co Ltd
Shaanxi Kanghui Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical intermediates in China. It is involved in the research, development, production, and sale of traditional Chinese medicine preparations; research and development of prepared slices of Chinese medicinal herbs and pharmaceutical intermediates; and pharmaceutical distribution of biolo… Read more